Think Sarasin
View our latest insights on the matters that impact your investments
HOUSE REPORT - Q2 2024
Staying the course
Investors have experienced a positive first quarter of the year, with markets reaching new highs against a backdrop in which economic and market traffic lights have increasingly turned green.
While this will likely continue to support global equity markets, quality and focus will be key going forward.
Guy Monson, our Chief Market Strategist, sets out what investors should focus on.
Latest insights
Equity outlook: Have markets underestimated big tech?
When a small clutch of stocks warrants a name, it implies shared characteristics. In the case of the Magnificent 7[1], they are all tech stocks that produced outstanding returns in 2023. But this is by no means the whole story. In fact, only two of the Magnificent 7...
Read more >
Private markets: is the journey worth it?
They are illiquid, hard to access, difficult to research and not especially transparent. So what accounts for the 16x growth of private assets over the past 30 years to become an £8 trillion juggernaut[1]? Not long after the dawn of my investment career – let’s say the 1990s...
Read more >
The devil’s in the detail: spotting climate winners and losers
We get to know our companies comprehensively. When it comes to climate change, we use a proprietary, forward-looking approach to weighing individual companies’ prospects as the world warms. Active investment managers spend a lot of time assessing the outlook for individual companies. But when it comes to estimating...
Read more >
Equity outlook Q1: Scope for further upside across equity markets
After a strong end to 2023, the prospects for equity markets and active stock selection are now encouraging. However, investors should remain flexible - 2024 may have more surprises in store. As 2022 drew to a close, most investors predicted a weaker US economy in 2023. How could...
Read more >
Investment themes: more than meets the AI
Sometimes it seems that the equity market can hold on to only one idea at a time. In 2023 that idea was artificial intelligence (AI), but 2024 could see the markets widen their interests. Market returns in 2023 surprised even the most optimistic of expectations. The ‘Magnificent Seven’,...
Read more >
Anti-obesity drugs: weighing the potential
‘Diabesity’ drugs have dominated headlines in recent months. The first of these was launched to little fanfare in the midst of the Covid pandemic in 2021, but as early adopters – often celebrities – showcased the seemingly miraculous results from these drugs, the world sat up and took...
Read more >